Advances in Prostate Cancer

Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively quickly. The cancer cells may spread from the prostate to other areas of the body, particularly the bones and lymph nodes. It may initially cause no symptoms. In later stages, it can lead to difficulty urinating, blood in the urine or pain in the pelvis, back, or when urinating. A disease known as benign prostatic hyperplasia may produce similar symptoms. Other late symptoms may include feeling tired due to low levels of red blood cells.


In the present book, fifteen typical literatures about prostate cancer published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on prostate imaging, biopsy, tumor markers, diet and lifestyle, pathophysiology, etc. We hope this book can demonstrate advances in prostate cancer as well as give references to the researchers, students and other related people.

Components of the Book:
  • Chapter 1
    A positive Real-Time Elastography (RTE) combined with a Prostate Cancer Gene 3 (PCA3) score above 35 convey a high probability of intermediate- or high-risk prostate cancer in patient admitted for primary prostate biopsy
  • Chapter 2
    Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer?
  • Chapter 3
    Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment
  • Chapter 4
    Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy
  • Chapter 5
    Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL
  • Chapter 6
    Benefits and harms of prostate cancer screening – predictions of the ONCOTYROL prostate cancer outcome and policy model
  • Chapter 7
    High risk human papilloma viruses (HPVs) are present in benign prostate tissues before development of HPV associated prostate cancer
  • Chapter 8
    Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns
  • Chapter 9
    Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition
  • Chapter 10
    Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody
  • Chapter 11
    The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases
  • Chapter 12
    Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer
Readership: Students, academics, teachers and other people attending or interested in prostate cancer.
Svein A. Haukaas, Department of Clinical Medicine, University of Bergen, Bergen, Norway

Angel Borque, Department of Urology, Hospital Universitario Miguel Servet, Zaragoza, Spain

Gerardo Sanz, Department of Statistical Methods, Universidad de Zaragoza, Zaragoza, Spain

Takeshi Kashiwabara, Department of Urology, Saku Central Hospital, Saku, Nagano, Japan

Murray D. Krahn, Toronto Health Economics and Technology Assessment (THETA) Collaborative, University of Toronto, Toronto, Canada

Uwe Siebert, Institute for Technology Assessment and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, USA

and more...
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top